PKU HealthCare Corp., (000788.SZ) is expected to see a net profit of 115 million to 145 million in 2024, an increase of 159.26% to 226.90%.

PKU HealthCare Corp., (000788.SZ) announced its performance forecast for the year 2024, expecting a net profit attributable to shareholders of the listed company of 1.15 billion to 1.45 billion yuan, a year-on-year increase of 159.26% to 226.90%. The year-on-year growth in operating performance in 2024 is mainly due to: 1. In the pharmaceutical industry sector, the company focuses on the three major areas of "anti-infection, analgesic, and psychiatric" drugs, with significant progress in key market expansion and changes in revenue structure of key products. Increases in sales volume of products such as meropenem for injection, levomethadone hydrochloride tablets, ceftriaxone sodium for injection, and ondansetron hydrochloride tablets, along with cost reduction and efficiency improvement measures, have driven the company's profit growth; 2. In the pharmaceutical distribution sector, benefiting from the gradual increase in downstream demand, the business income scale of the company's wholly-owned subsidiary Beijing Beiyi Pharmaceuticals Co., Ltd. has increased year-on-year, leading to a growth in net profit.